HomeMost PopularAbbVie Stock: An In-Depth Analysis of the Third Quarter 2023 Results

AbbVie Stock: An In-Depth Analysis of the Third Quarter 2023 Results

Actionable Trade Ideas

always free

AbbVie (NYSE:ABBV) is a leading global pharmaceutical company headquartered in North Chicago.


In this article, we will delve into AbbVie’s recent financial results for the third quarter of 2023 and explore the factors influencing its stock performance.

Positive Financial Results

During the third quarter of 2023, AbbVie reported strong financial results, which exceeded market expectations. These optimistic results have influenced our investment outlook for the company.

Rise in Revenue

AbbVie’s revenue has experienced consistent growth, demonstrating the company’s ability to thrive in a highly competitive market. This growth has been driven by the increased sales of AbbVie’s essential drugs and the successful introduction of new products in the market.

Key Neuroscience Products Driving Sales

AbbVie’s management raised the financial guidance for its adjusted diluted EPS for 2023 due to robust sales of the company’s key neuroscience products. Qulipta, a medication used for the prevention of migraines, witnessed a substantial increase in sales, contributing to the overall revenue growth of AbbVie.

Sales of Qulipta

The oral administration of Qulipta, along with its mechanism of action in blocking CGRP receptors, has made it an effective treatment against episodic and chronic migraines. Sales of Qulipta amounted to $132 million in the third quarter of 2023, representing a remarkable 112.9% increase compared to the previous year.

Dividend Aristocrats Status

AbbVie has established a track record of consistently increasing its quarterly cash dividend. The company’s recent dividend hike of 4.7%, resulting in a dividend of $1.55 per share, showcases AbbVie’s commitment to its shareholders. Furthermore, AbbVie’s dividend yield surpasses 4%, making it an appealing investment option for long-term investors.

Immunology Segment Challenges

Despite AbbVie’s overall positive financial performance, the company faces challenges in its immunology segment. The introduction of an increasing number of Humira biosimilars has impacted the revenue growth rate of AbbVie. As a result, we maintain a “hold” rating for AbbVie until these challenges are mitigated.

Financial Outlook for the Fourth Quarter 2023

Seeking Alpha projects AbbVie’s revenue for the fourth quarter of 2023 to range between $13.6 billion and $14.03 billion. Although this represents a 10.1% decline compared to the previous year, it is expected to beat analysts’ expectations for the quarter.

According to our model, AbbVie’s total revenue is anticipated to reach $13.7 billion. This slight decline in revenue can be attributed to the lower sales of Humira, Imbruvica, and Botox, as well as the strengthening of the US dollar against other currencies.

Earnings per Share (EPS)

For the fourth quarter of 2023, AbbVie’s EPS is estimated to be in the range of $2.88 to $3.07, indicating a 2.4% increase from the previous quarter. Our model predicts AbbVie’s EPS to be slightly lower at $2.91, representing an 18.7% decrease compared to the previous year.

Valuation Metrics

AbbVie’s Non-GAAP P/E [TTM] is 11.66x, which is 28.67% lower than the sector average. However, AbbVie’s Non-GAAP P/E [FWD] is 12.51x, 24.12% higher than the five-year average. These valuation metrics provide insights into the market’s perception of AbbVie’s future prospects.


AbbVie’s financial report for the third quarter of 2023 showcases the company’s resilience and growth potential within the pharmaceutical industry. While challenges persist in the immunology segment, AbbVie’s strong revenue and dividend track record make it an attractive long-term investment option.

As a result, we maintain our “hold” rating for AbbVie, as we believe its foray into neurological drugs will drive future growth and counterbalance potential challenges in other segments.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.